[1. Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med. 2008; 121(8 Suppl 2):S3-10. doi: 10.1016/j.amjmed.2008.05.021.10.1016/j.amjmed.2008.05.021]Open DOISearch in Google Scholar
[2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014; 30(2):170-6. doi: 10.4103/0970-1591.126900.10.4103/0970-1591.126900]Open DOISearch in Google Scholar
[3. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015; 22 Suppl 1:1-6.]Search in Google Scholar
[4. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16.10.1016/S0090-4295(01)01298-5]Search in Google Scholar
[5. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006; 97 Suppl 2:3-6; discussion 21-2. doi: 10.1111/j.1464-410X.2006.06097.x.10.1111/j.1464-410X.2006.06097.x]Open DOISearch in Google Scholar
[6. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18 Suppl:14-9.]Search in Google Scholar
[7. Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. Int Urol Nephrol. 2016; 48(5):645-56. doi: 10.1007/s11255-015-1206-7.10.1007/s11255-015-1206-7]Open DOISearch in Google Scholar
[8. Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012; 4(2):77-83. doi: 10.1177/1756287212437361.10.1177/1756287212437361]Search in Google Scholar
[9. Fourcade RO, Lacoin F, Roupret M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30(3):419-26. doi: 10.1007/s00345-011-0756-2.10.1007/s00345-011-0756-2]Open DOISearch in Google Scholar
[10. Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015; 94(2):187-93. doi: 10.1159/000366521.10.1159/000366521]Search in Google Scholar
[11. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998; 37(2):77-83. doi: 10.1002/(SICI)1097-0045(19981001)37:2<77::AIDPROS3>3.0.CO;2-I.10.1002/(SICI)1097-0045(19981001)37:2<77::AIDPROS3>3.0.CO;2-]Open DOISearch in Google Scholar
[12. Bayne CW, Donnelly F, Ross M, et al. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999; 40(4):232-41. doi: 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0.10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0]Open DOISearch in Google Scholar
[13. Latil A, Libon C, Templier M, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012; 110(6 Pt B):E301-7. doi: 10.1111/j.1464-410X.2012.11144.x.10.1111/j.1464-410X.2012.11144.x22520557]Search in Google Scholar
[14. Scaglione F, Lucini V, Pannacci M, et al. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012; 16(5):569-74.]Search in Google Scholar
[15. Sirab N, Robert G, Fasolo V, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013; 14(7):14301-20. doi: 10.3390/ijms140714301.10.3390/ijms140714301374224523846725]Open DOISearch in Google Scholar
[16. European Medicines Agency (2015) Committee on Herbal Medicinal Products (HMPC). Assessment report on Serenoa repens (W, Bartram) Small, fructus EMA/HMPC/137250/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal-HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed May 2017.]Search in Google Scholar
[17. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015; 67(6):1099-109. doi: 10.1016/j.eururo.2014.12.038.10.1016/j.eururo.2014.12.03825613154]Open DOISearch in Google Scholar
[18. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.10.1097/01.ju.0000078083.38675.7912853821]Open DOISearch in Google Scholar
[19. Andriole GL, McCullum-Hill C, Sandhu GS, et al.; CAMUS Study Group. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013; 189(2):486-92. doi: 10.1016/j.juro.2012.09.037.10.1016/j.juro.2012.09.037397945123253958]Open DOISearch in Google Scholar
[20. Fagelman E, Lowe FC. Saw Palmetto Berry as a Treatment for BPH. Rev Urol. 2001 Summer; 3(3):134-8.]Search in Google Scholar
[21. Kim SW. Phytotherapy: emerging therapeutic option in urologic disease. Transl Androl Urol. 2012; 1(3):181-91. doi: 10.3978/j.issn.2223-4683.2012.05.10.10.3978/j.issn.2223-4683.2012.05.10470825026816707]Open DOISearch in Google Scholar
[22. Argirović A, Argirović D. Does the Addition of Serenoa Repens to Tamsulosin Improve Its Therapeutical Efficacy in Benign Prostatic Hyperplasia? Vojnosanit Pregl. 2013; 70(12):1091-6.10.2298/VSP110620029A24450252]Search in Google Scholar
[23. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011; 3(4):193-8. doi: 10.1177/1756287211418725.10.1177/1756287211418725317570321969849]Search in Google Scholar
[24. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. NEJM. 2006; 354(6):557-66. doi: 10.1056/NEJMoa053085.10.1056/NEJMoa05308516467543]Open DOISearch in Google Scholar
[25. Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA. 2011; 306(12):1344-51. doi: 10.1001/jama.2011.1364.10.1001/jama.2011.1364332634121954478]Open DOISearch in Google Scholar
[26. MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012; 109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x.10.1111/j.1464-410X.2012.11172.x351328222551330]Open DOISearch in Google Scholar
[27. Ooi SL, Pak SC. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and its Clinical Implications in Naturopathic Medicine. J Altern Complement Med. 2017 Apr 24. doi: 10.1089/acm.2016.0302.10.1089/acm.2016.030228436684]Open DOISearch in Google Scholar
[28. Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009; 30(3):227-81. doi: 10.1038/aps.2009.1.10.1038/aps.2009.1400240219262550]Open DOISearch in Google Scholar
[29. De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol. 2014; 14:63. doi: 10.1186/1471-2490-14-63.10.1186/1471-2490-14-63413642025112532]Open DOISearch in Google Scholar
[30. Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009; 32(8):637-47. doi: 10.2165/00002018-200932080-00003.10.2165/00002018-200932080-0000319591529]Search in Google Scholar